Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Giovanna Carrà 1 , Cristina Panuzzo 1 , Davide Torti 1,2 , Guido Parvis 2,3 , Sabrina Crivellaro 1 , Ubaldo Familiari 4 , Marco Volante 4,5 , Deborah Morena 5 , Marcello Francesco Lingua 5 , Mara Brancaccio 6 , Angelo Guerrasio 1 , Pier Paolo Pandolfi 7 , Giuseppe Saglio 1,2,3 , Riccardo Taulli 5 and Alessandro Morotti 1 1 Department of Clinical and Biological Sciences, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy 2 Division of Internal Medicine - Hematology, San Luigi Gonzaga Hospital, Orbassano, Italy 3 Division of Hematology, Azienda Ospedaliera, Mauriziano, Torino, Italy 4 Division of Pathology, San Luigi Hospital, Orbassano, Italy 5 Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy 6 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 7 Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Correspondence to: Alessandro Morotti, email: // Riccardo Taulli, email: // Keywords : chronic lymphocytic leukemia, USP7, PTEN, miR181, miR338 Received : June 14, 2016 Accepted : February 20, 2017 Published : March 17, 2017 Abstract Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-expressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53- wild type and -null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Self-citationUbiquitination regulates PTEN nuclear import and tumor suppression
Trotman, L. C., Wang, X., Alimonti, A., Chen, Z., Teruya-Feldstein, J., Yang, H., Pavletich, N. P., Carver, B. S., Cordon-Cardo, C., Erdjument-Bromage, H., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.040 · Cited by 748 · cited 1×
“GFP and PTEN constructs were described elsewhere [20, 59].”
Self-citationChauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 4×
“showed that pharmacological inhibition of the de-ubiquitinase USP7 strongly induces apoptosis in multiple myeloma cells resistant to conventional and bortezomib-based therapies [17].”
BackgroundMethodInfluentialThe deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07290 · Cited by 548
Self-citationNuclear PTEN controls DNA repair and sensitivity to genotoxic stress
Bassi, C., Ho, J., Srikumar, T., Dowling, R. J. O., Gorrini, C., Miller, S. J., Mak, T. W., Neel, B. G., Raught, B., & Stambolic, V. (2013) · Science · doi:10.1126/science.1236188 · Cited by 403
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 1×
“Recently a few inhibitors have been developed to specifically target USP7 with promising results in different cancer models [17, 44-50].”
BackgroundStress-mediated nuclear stabilization of p53 is regulated by ubiquitination and importin-α3 binding
Marchenko, N. D., Hanel, W., Li, D., Becker, K., Reich, N., & Moll, U. M. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.173 · Cited by 123 · cited 1×
“USP7 is expressed both in the nucleus and in the cytoplasm of representative primary CLL samples and CLL cell lines, MEC-1 and EHEB (Figure 1D), as observed in other cellular models [31-34].”
Result
Cited by
Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0619-z · Cited by 303
RetractedUSP7: Structure, substrate specificity, and inhibition
Pozhidaeva, A., & Bezsonova, I. (2019) · DNA Repair · doi:10.1016/j.dnarep.2019.02.005 · Cited by 178
Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases.
Bhattacharya, S., Chakraborty, D., Basu, M., & Ghosh, M. K. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0012-y · Cited by 162
“Metformin is primarily used to regulate AMPK–mTOR signaling, inhibits HAUSP activity and enhances growth inhibition in cancer cells.111 The natural compound spongiacidin C (from the marine sponge Stylissa massa) is another therapeutic agent.112 Current findings related to chronic lymphocytic leukemia (CLL) suggest tha…”
BackgroundXie, P., Wang, H., Xie, J., Huang, Z., Chen, S., Cheng, X., Zhang, X., Liu, F., Li, Y., & Huang, D. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111037 · Cited by 16
Metadata
- Authors
- Carrà, G., Panuzzo, C., Torti, D., Parvis, G., Crivellaro, S., Familiari, U., Volante, M., Morena, D., Lingua, M. F., Brancaccio, M., Guerrasio, A., Pandolfi, P. P., Saglio, G., Taulli, R., & Morotti, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-03-17
- Volume
- 8
- Issue
- 22
- Pages
- 35508-35522
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2597394530
- Cited by
- 77
- References
- 7
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. https://app.cochat.ai/papers/10.18632/oncotarget.16348
- The paper
- Carrà, G., Panuzzo, C., Torti, D., Parvis, G., Crivellaro, S., Familiari, U., Volante, M., Morena, D., Lingua, M. F., Brancaccio, M., Guerrasio, A., Pandolfi, P. P., Saglio, G., Taulli, R., & Morotti, A. (2017). Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget. https://doi.org/10.18632/oncotarget.16348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.